Posip Duo Sustained Release Tablet 10/1000 mg

Adult dose

The dosage of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, not exceeding the maximum recommended doses of 10 mg dapagliflozin and 2000 mg sustained-release metformin. This medicine is generally administered once daily with the evening meal. The maximum dosage is dapagliflozin 10 mg/sustained-release metformin 2000 mg once daily, given as 2 tablets of 5 mg/1000 mg.

This medicine is used for blood sugar control and should not be administered to patients with poor kidney function or severe renal impairment. Patients should consult a doctor immediately if dehydration, serious infections, or cardiovascular problems occur while taking this medicine, and drug administration may need to be temporarily discontinued in these situations. Pregnant or nursing women should not take this medicine, and those receiving treatment should quickly receive treatment if symptoms of genital infections or urinary tract infections occur, as the risk of such infections may increase. This medicine may cause hypoglycemia; therefore, when used with insulin or sulfonylureas, careful monitoring of blood sugar changes is required and dose adjustments may be necessary. Patients should undergo regular kidney function tests before and during treatment, and if kidney function deteriorates, the use of this medicine should be discontinued. Additionally, this medicine may cause decreased fluid volume or low blood pressure, so particularly elderly patients or those taking diuretics should closely monitor their blood pressure and fluid status. If surgery or tests using iodinated contrast agents are planned while taking this medicine, it should be discontinued at least 48 hours prior and restarted only after confirming kidney function. This medicine may reduce vitamin B12 levels, so it is advisable to regularly check vitamin B12 concentrations during prolonged use. Excessive alcohol consumption may increase the risk of side effects of this medicine, so caution is required. In the event of overdose, seek appropriate medical attention immediately, and this medicine has not been established for safety and efficacy in children. Finally, this medicine should be kept out of the reach of children and stored in its original container to maintain quality.

Serious side effects

Severe lactic acidosis (Symptoms of lactic acidosis: fatigue, muscle pain, breathlessness, weakness, abdominal pain, hypothermia, hypotension, resistant bradycardia arrhythmias), severe allergic reactions (hives, severe swelling, chest tightness, breathing difficulty, cold sweat, pallor), severe skin adverse reactions (severe rash with fever, blisters, skin peeling, pain in oral/ocular mucosa), respiratory problems (shortness of breath or difficulty breathing, asthma attacks, cough + fever)

Mild side effects

Hypoglycemia, vulvovaginitis, balanitis and related genital infections, urinary tract infection, decreased fluid volume (including dehydration, hypovolemia, hypotension), thirst, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, vulvar itching, genital itching, increased hematocrit, decreased creatinine clearance at the beginning of treatment, dyslipidemia, increased serum creatinine, increased serum urea, weight loss, diarrhea, nausea/vomiting, vitamin deficiency.

This medicine should be stored in a tightly sealed container to prevent air or moisture ingress, at a temperature between 1 to 30 degrees Celsius. This storage condition will maintain the medicine's effectiveness and ensure safe usage.

Appearance

Yellow, oval-shaped sustained-release film-coated tablet with convex sides

Package unit

30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle